vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and BALCHEM CORP (BCPC). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $270.7M, roughly 1.0× BALCHEM CORP). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 14.9%, a 81.4% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs 8.1%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 7.5%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Balchem Corp is a global specialty chemicals and nutritional ingredients provider that develops, manufactures and distributes application-specific products for human nutrition, animal health, pharmaceutical and industrial end markets, serving customers across North America, Europe and Asia Pacific.
ACAD vs BCPC — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $270.7M |
| Net Profit | $273.6M | $40.3M |
| Gross Margin | 90.8% | — |
| Operating Margin | 6.1% | 20.5% |
| Net Margin | 96.3% | 14.9% |
| Revenue YoY | 9.4% | 8.1% |
| Net Profit YoY | 90.3% | 8.7% |
| EPS (diluted) | $1.61 | $1.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $270.7M | ||
| Q4 25 | $284.0M | $263.6M | ||
| Q3 25 | $278.6M | $267.6M | ||
| Q2 25 | $264.6M | $255.5M | ||
| Q1 25 | $244.3M | $250.5M | ||
| Q4 24 | $259.6M | $240.0M | ||
| Q3 24 | $250.4M | $239.9M | ||
| Q2 24 | $242.0M | $234.1M |
| Q1 26 | — | $40.3M | ||
| Q4 25 | $273.6M | $39.2M | ||
| Q3 25 | $71.8M | $40.3M | ||
| Q2 25 | $26.7M | $38.3M | ||
| Q1 25 | $19.0M | $37.1M | ||
| Q4 24 | $143.7M | $33.6M | ||
| Q3 24 | $32.8M | $33.8M | ||
| Q2 24 | $33.4M | $32.1M |
| Q1 26 | — | — | ||
| Q4 25 | 90.8% | 35.6% | ||
| Q3 25 | 92.2% | 35.7% | ||
| Q2 25 | 92.2% | 36.4% | ||
| Q1 25 | 91.7% | 35.2% | ||
| Q4 24 | 91.6% | 36.0% | ||
| Q3 24 | 92.5% | 35.6% | ||
| Q2 24 | 92.5% | 35.5% |
| Q1 26 | — | 20.5% | ||
| Q4 25 | 6.1% | 19.8% | ||
| Q3 25 | 12.8% | 20.4% | ||
| Q2 25 | 12.2% | 20.1% | ||
| Q1 25 | 7.9% | 20.4% | ||
| Q4 24 | 59.1% | 19.8% | ||
| Q3 24 | 12.6% | 20.0% | ||
| Q2 24 | 12.6% | 19.6% |
| Q1 26 | — | 14.9% | ||
| Q4 25 | 96.3% | 14.9% | ||
| Q3 25 | 25.8% | 15.1% | ||
| Q2 25 | 10.1% | 15.0% | ||
| Q1 25 | 7.8% | 14.8% | ||
| Q4 24 | 55.4% | 14.0% | ||
| Q3 24 | 13.1% | 14.1% | ||
| Q2 24 | 13.8% | 13.7% |
| Q1 26 | — | $1.25 | ||
| Q4 25 | $1.61 | $1.21 | ||
| Q3 25 | $0.42 | $1.24 | ||
| Q2 25 | $0.16 | $1.17 | ||
| Q1 25 | $0.11 | $1.13 | ||
| Q4 24 | $0.86 | $1.03 | ||
| Q3 24 | $0.20 | $1.03 | ||
| Q2 24 | $0.20 | $0.98 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $72.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $1.3B |
| Total Assets | $1.6B | $1.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $72.9M | ||
| Q4 25 | $177.7M | $74.6M | ||
| Q3 25 | $258.0M | $65.1M | ||
| Q2 25 | $253.6M | $65.4M | ||
| Q1 25 | $217.7M | $49.9M | ||
| Q4 24 | $319.6M | $49.5M | ||
| Q3 24 | $155.1M | $73.7M | ||
| Q2 24 | $177.1M | $63.7M |
| Q1 26 | — | $1.3B | ||
| Q4 25 | $1.2B | $1.3B | ||
| Q3 25 | $917.3M | $1.3B | ||
| Q2 25 | $822.4M | $1.3B | ||
| Q1 25 | $765.2M | $1.2B | ||
| Q4 24 | $732.8M | $1.1B | ||
| Q3 24 | $577.2M | $1.2B | ||
| Q2 24 | $516.7M | $1.1B |
| Q1 26 | — | $1.7B | ||
| Q4 25 | $1.6B | $1.7B | ||
| Q3 25 | $1.3B | $1.7B | ||
| Q2 25 | $1.2B | $1.7B | ||
| Q1 25 | $1.1B | $1.6B | ||
| Q4 24 | $1.2B | $1.6B | ||
| Q3 24 | $976.9M | $1.6B | ||
| Q2 24 | $914.1M | $1.6B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $40.1M |
| Free Cash FlowOCF − Capex | — | $33.8M |
| FCF MarginFCF / Revenue | — | 12.5% |
| Capex IntensityCapex / Revenue | — | 2.3% |
| Cash ConversionOCF / Net Profit | -0.18× | 0.99× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $40.1M | ||
| Q4 25 | $-48.7M | $67.3M | ||
| Q3 25 | $74.3M | $65.6M | ||
| Q2 25 | $64.0M | $47.3M | ||
| Q1 25 | $20.3M | $36.5M | ||
| Q4 24 | $40.4M | $52.3M | ||
| Q3 24 | $63.2M | $51.3M | ||
| Q2 24 | $25.0M | $45.0M |
| Q1 26 | — | $33.8M | ||
| Q4 25 | — | — | ||
| Q3 25 | $73.9M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $63.2M | — | ||
| Q2 24 | — | — |
| Q1 26 | — | 12.5% | ||
| Q4 25 | — | — | ||
| Q3 25 | 26.5% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 25.2% | — | ||
| Q2 24 | — | — |
| Q1 26 | — | 2.3% | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | — | — |
| Q1 26 | — | 0.99× | ||
| Q4 25 | -0.18× | 1.72× | ||
| Q3 25 | 1.03× | 1.63× | ||
| Q2 25 | 2.40× | 1.23× | ||
| Q1 25 | 1.07× | 0.98× | ||
| Q4 24 | 0.28× | 1.56× | ||
| Q3 24 | 1.93× | 1.52× | ||
| Q2 24 | 0.75× | 1.40× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
BCPC
Segment breakdown not available.
